These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28698044)

  • 21. Clinical and operational value of the extensively drug-resistant tuberculosis definition.
    Migliori GB; Besozzi G; Girardi E; Kliiman K; Lange C; Toungoussova OS; Ferrara G; Cirillo DM; Gori A; Matteelli A; Spanevello A; Codecasa LR; Raviglione MC;
    Eur Respir J; 2007 Oct; 30(4):623-6. PubMed ID: 17690121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
    Ramachandran R; Nalini S; Chandrasekar V; Dave PV; Sanghvi AS; Wares F; Paramasivan CN; Narayanan PR; Sahu S; Parmar M; Chadha S; Dewan P; Chauhan LS
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1154-60. PubMed ID: 19723407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
    Javaid A; Hasan R; Zafar A; Chaudry MA; Qayyum S; Qadeer E; Shaheen Z; Agha N; Rizvi N; Afridi MZ; Chima MK; Khan AR; Ghafoor A; Khan S; Awan SR; Akhtar S; Choudry K; Iqbal ZH; Ansarie M; Ahmad N
    Int J Tuberc Lung Dis; 2017 Mar; 21(3):303-308. PubMed ID: 28225340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018.
    Mutayoba BK; Ershova J; Lyamuya E; Hoelscher M; Heinrich N; Kilale AM; Range NS; Ngowi BJ; Ntinginya NE; Mfaume SM; Nkiligi E; Doulla B; Lyimo J; Kisonga R; Kingalu A; Lema Y; Kondo Z; Pletschette M
    Trop Med Int Health; 2022 Oct; 27(10):891-901. PubMed ID: 36089572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
    Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa.
    Müller B; Chihota VN; Pillay M; Klopper M; Streicher EM; Coetzee G; Trollip A; Hayes C; Bosman ME; Gey van Pittius NC; Victor TC; Gagneux S; van Helden PD; Warren RM
    PLoS One; 2013; 8(8):e70919. PubMed ID: 24058399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-Based Drug Resistance Surveillance of Multidrug-Resistant Tuberculosis in Taiwan, 2007-2014.
    Chuang PH; Wu MH; Fan SY; Lin KY; Jou R
    PLoS One; 2016; 11(11):e0165222. PubMed ID: 27846235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
    Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A reduction in anti-tuberculosis drug resistance after the implementation of the national "STOP TB" program in central Taiwan, 2003-2007.
    Huang WC; Chen CH; Huang CC; Wu KM; Chiou CS; Lin CF; Chen JH; Shen GH
    Jpn J Infect Dis; 2013; 66(2):89-95. PubMed ID: 23514903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India.
    Paramasivan CN; Rehman F; Wares F; Sundar Mohan N; Sundar S; Devi S; Narayanan PR
    Int J Tuberc Lung Dis; 2010 Feb; 14(2):243-6. PubMed ID: 20074419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevalence and risk factors on the resistance related to second-line drugs among multi-drug resistant tuberculosis cases in Shanghai, China].
    Li J; Zhang YY; Gui XH; Yuan ZA; Pan QC; Mei J; Shen X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):796-8. PubMed ID: 22967331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical against molecular-genetic methods for susceptibility testing of antituberculotics.
    Porvaznik I; Mokry J; Solovic I
    Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.
    Cambau E; Viveiros M; Machado D; Raskine L; Ritter C; Tortoli E; Matthys V; Hoffner S; Richter E; Perez Del Molino ML; Cirillo DM; van Soolingen D; Böttger EC
    J Antimicrob Chemother; 2015 Mar; 70(3):686-96. PubMed ID: 25587993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012-2014.
    Lemus D; Echemendía M; Díaz R; Llanes MJ; Suárez L; Marrero A
    MEDICC Rev; 2017 Jan; 19(1):10-15. PubMed ID: 28225540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and characterization of drug-resistant tuberculosis in a local hospital of Northeast China.
    Yang Y; Zhou C; Shi L; Meng H; Yan H
    Int J Infect Dis; 2014 May; 22():83-6. PubMed ID: 24556164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
    Dhingra VK; Rajpal S; Mittal A; Hanif M
    Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.